Therapy News and Research

RSS

Biovest receives Rapporteur and Co-Rapporteur designation for BiovaxID personalized cancer vaccine

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that the European Medicines Agency (EMA) has notified Biovest regarding the official designation of the Rapporteur and Co-Rapporteur for BiovaxID, a personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma.

30 Jul 2012

FDA grants Senesco's SNS01-T orphan-drug designation to treat lymphomas

Senesco Technologies, Inc. reported today that it was informed on July 26th that the U.S. Food and Drug Administration has granted orphan-drug designation for the company's lead drug candidate SNS01-T for treatment of both mantle cell lymphoma and diffuse large B-cell lymphoma.

30 Jul 2012

Osiris second quarter biosurgery product revenue increases 43% from previous quarter

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today its results for the second quarter ended June 30, 2012.

30 Jul 2012

Advaxis reports continued positive patient survival pattern in ADXS-HPV Phase 2 cervical cancer trial

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, presented updated preliminary data from an ongoing randomized Phase 2 trial of ADXS-HPV being conducted in India in women with recurrent/refractory cervical cancer who have failed previous cytotoxic therapy.

30 Jul 2012

Tenth patient treated in ACT's hESC derived RPE cell trial for SMD

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, today announced treatment of the final patient in the first patient cohort in its Phase 1/2 clinical trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).

30 Jul 2012

Dosimetry data from SalutarisMD episcleral brachytherapy device clinical study on wet AMD

At the American Association of Physicists in Medicine (AAPM) Annual Meeting yesterday, Russell J. Hamilton, PhD, Professor and Physics Section Head, University of Arizona Department of Radiation Oncology, reviewed dosimetry data for a minimally invasive episcleral brachytherapy device developed by Salutaris Medical Devices, Inc. (SalutarisMD) to treat Wet AMD (Age-related Macular Degeneration), the leading cause of vision loss and blindness.

30 Jul 2012

Patients with plantar fasciitis experience less pain and improved QOL after standard radiation therapy

Patients with plantar fasciitis (painful bone heel spur) experience significantly less pain and improved quality of life following a standard dose of external beam radiation therapy, a common cancer treatment similar to receiving an X-ray, according to a randomized, cooperative group study that was published online July 25, 2012, in the International Journal of Radiation, Oncology, Biology, Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).

30 Jul 2012

New assay method finds evidence of clonal evolution in chronic lymphocytic leukemia

Using a new assay method to study tumor cells, researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center have found evidence of clonal evolution in chronic lymphocytic leukemia (CLL).

30 Jul 2012

New compound effective at blocking damage to the retina in diabetic retinopathy

Researchers at the University of Michigan Kellogg Eye Center have identified a compound that could interrupt the chain of events that cause damage to the retina in diabetic retinopathy. The finding is significant because it could lead to a novel therapy that targets two mechanisms at the root of the disease: inflammation and the weakening of the blood barrier that protects the retina.

30 Jul 2012

Neurotez receives U.S. patent for Leptin to treat Alzheimer's

Neurotez, Inc. today announced the grant of U.S. Patent number 8,227,408 by the United States Patent and Trademark Office covering the company's lead product candidate, Leptin. The patent protects use of the hormone Leptin for treating a progressive cognitive disease, disorder or condition, such as Alzheimer's disease (AD), resulting from accumulation of an amyloid peptide or for improving resilience of cognitive function by modulating the accumulation of the amyloid peptide in brain.

30 Jul 2012

Pre-hospital electrocardiography offers more timely diagnosis of heart attack

A study conducted by researchers from the University of California, San Diego School of Medicine along with colleagues from Rural/Metro Ambulance San Diego and the San Diego Fire-Rescue Department, shows that emergency medical personnel can obtain an electrocardiogram (ECG) in the field for chest pain patients without an increase in scene time or transport time to the hospital.

30 Jul 2012

Group yoga can boost motor function and balance in stroke survivors

Group yoga can improve motor function and balance in stroke survivors, even if they don't begin yoga until six months or more after the stroke, according to "Post-Stroke Balance Improves With Yoga: A Pilot Study," published online July 26 in the journal Stroke.

30 Jul 2012

Barefoot running in and of itself is neither good nor bad

Ethiopian runner Abebe Bikila made history when he earned a gold medal at the 1960 Summer Olympics in Rome. His speed and agility won him the gold, but it was barefoot running that made him a legend.

30 Jul 2012

Researchers isolate elusive human gene that causes NMNAT1-related Leber congenital amaurosis

Researchers from the Massachusetts Eye and Ear Infirmary, The Children's Hospital of Philadelphia, Loyola University Chicago Health Sciences Division and their collaborators have isolated an elusive human gene that causes a common form of Leber congenital amaurosis (LCA), a relatively rare but devastating form of early-onset blindness. The new LCA gene is called NMNAT1.

30 Jul 2012

Cedars-Sinai to develop stem cell treatments for patients with ALS

Cedars-Sinai Regenerative Medicine Institute today was awarded a $17.8 million grant from the California Institute for Regenerative Medicine to develop stem cell treatments for patients with ALS, also known as Lou Gehrig's Disease, a progressive, fatal and currently incurable neurodegenerative disease.

30 Jul 2012

Ephrin-A5 blocks formation of new connections between neurons after stroke

Researchers at UCLA have identified a novel molecule in the brain that, after stroke, blocks the formation of new connections between neurons. As a result, it limits the brain's recovery. In a mouse model, the researchers showed that blocking this molecule-called ephrin-A5--induces axonal sprouting, that is, the growth of new connections between the brain's neurons, or cells, and as a result promotes functional recovery.

29 Jul 2012

Brief treatments with accelerated resolution therapy reduce symptoms associated with PTSD

Researchers at the University of South Florida (USF) College of Nursing have shown that brief treatments with Accelerated Resolution Therapy (ART) substantially reduce symptoms associated with post-traumatic stress disorder (PTSD) including, depression, anxiety, sleep dysfunction and other physical and psychological symptoms.

28 Jul 2012

Takeda resubmits alogliptin and fixed-dose combination therapy NDAs with FDA

Furiex Pharmaceuticals, Inc. today confirmed that Takeda Pharmaceutical Company Limited announced that its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. has resubmitted New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for alogliptin and fixed-dose combination therapy alogliptin and pioglitazone for the treatment of type 2 diabetes in adults.

28 Jul 2012

Research presented at AIDS 2012 conference renews hope of cure for AIDS

Two studies presented at the XIX International AIDS Conference (AIDS 2012) and one published Wednesday in the British journal Nature "have given researchers renewed hope that a cure for AIDS may be possible," the Washington Post reports.

28 Jul 2012

Rituximab also benefits patients with kidney disorder

A drug commonly used to treat immune disorders such as lymphoma and arthritis also benefits patients with an immune disorder of the kidneys that can lead to kidney failure, according to a study appearing in an upcoming issue of new study in the Journal of the American Society of Nephrology (JASN).

28 Jul 2012

Therapy News and Research

Biovest receives Rapporteur and Co-Rapporteur designation for BiovaxID personalized cancer vaccine

FDA grants Senesco's SNS01-T orphan-drug designation to treat lymphomas

Osiris second quarter biosurgery product revenue increases 43% from previous quarter

Advaxis reports continued positive patient survival pattern in ADXS-HPV Phase 2 cervical cancer trial

Tenth patient treated in ACT's hESC derived RPE cell trial for SMD

Dosimetry data from SalutarisMD episcleral brachytherapy device clinical study on wet AMD

Patients with plantar fasciitis experience less pain and improved QOL after standard radiation therapy

New assay method finds evidence of clonal evolution in chronic lymphocytic leukemia

New compound effective at blocking damage to the retina in diabetic retinopathy

Neurotez receives U.S. patent for Leptin to treat Alzheimer's

Pre-hospital electrocardiography offers more timely diagnosis of heart attack

Group yoga can boost motor function and balance in stroke survivors

Barefoot running in and of itself is neither good nor bad

Researchers isolate elusive human gene that causes NMNAT1-related Leber congenital amaurosis

Cedars-Sinai to develop stem cell treatments for patients with ALS

Ephrin-A5 blocks formation of new connections between neurons after stroke

Brief treatments with accelerated resolution therapy reduce symptoms associated with PTSD

Takeda resubmits alogliptin and fixed-dose combination therapy NDAs with FDA

Research presented at AIDS 2012 conference renews hope of cure for AIDS

Rituximab also benefits patients with kidney disorder

Industry Focus eBook - Cell biology (5th edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News